» Articles » PMID: 35245816

Genome-wide DNA Methylation Profiling Identifies Epigenetic Changes in CD4+ and CD14+ Cells of Multiple Sclerosis Patients

Overview
Specialty Neurology
Date 2022 Mar 4
PMID 35245816
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple sclerosis (MS) is a chronic autoimmune and degenerative disease of the central nervous system, which develops in genetically predisposed individuals upon exposure to environmental influences. Environmental triggers of MS, such as viral infections or smoking, were demonstrated to affect DNA methylation, and thus to involve this important epigenetic mechanism in the development of pathological process. To identify MS-associated DNA methylation hallmarks, we performed genome-wide DNA methylation profiling of two cell populations (CD4+ T-lymphocytes and CD14+ monocytes), collected from the same treatment-naive relapsing-remitting MS patients and healthy subjects, using Illumina 450 K methylation arrays. We revealed significant changes in DNA methylation for both cell populations in MS. In CD4+ cells of MS patients the majority of differentially methylated positions (DMPs) were shown to be hypomethylated, while in CD14+ cells - hypermethylated. Differential methylation of HLA-DRB1 gene in CD4+ and CD14+ cells was associated with carriage of DRB1*15 allele independently from the disease status. Besides, about 20% of identified DMPs were shared between two cell populations and had the same direction of methylation changes; they may be involved in basic epigenetic processes occuring in MS. These findings suggest that the epigenetic mechanism of DNA methylation in immune cells contributes to MS; further studies are now required to validate these results and understand their functional significance.

Citing Articles

Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis.

Fondelli F, Willemyns J, Domenech-Garcia R, Mansilla M, Godoy-Tena G, Ferrete-Bonastre A J Clin Invest. 2024; 134(21).

PMID: 39287981 PMC: 11527446. DOI: 10.1172/JCI178949.


A Comprehensive Examination of the Role of Epigenetic Factors in Multiple Sclerosis.

Manna I, De Benedittis S, Porro D Int J Mol Sci. 2024; 25(16).

PMID: 39201606 PMC: 11355011. DOI: 10.3390/ijms25168921.


Editorial: Understanding sex-specific issues in MS and its animal models: natural history, management and mechanisms.

Zeydan B, Rangachari M, Kantarci O Front Neurol. 2024; 15:1366126.

PMID: 38322587 PMC: 10844553. DOI: 10.3389/fneur.2024.1366126.


Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis.

Lorefice L, Pitzalis M, Murgia F, Fenu G, Atzori L, Cocco E Front Genet. 2023; 14:1076421.

PMID: 36793897 PMC: 9922720. DOI: 10.3389/fgene.2023.1076421.


Sex, aging and immunity in multiple sclerosis and experimental autoimmune encephalomyelitis: An intriguing interaction.

Boziki M, Theotokis P, Kesidou E, Karafoulidou E, Konstantinou C, Michailidou I Front Neurol. 2023; 13:1104552.

PMID: 36698908 PMC: 9869255. DOI: 10.3389/fneur.2022.1104552.